Conmed (CNMD) Tops Q3 EPS by 5c

Conmed (NASDAQ: CNMD) reported Q3 EPS of $0.44, $0.05 better than the analyst estimate of $0.39. Revenue for the quarter came in at $175 million versus the consensus estimate of $173.3 million.

Conmed sees FY2014 EPS of $1.85-$1.95, versus the consensus of $1.87.

"We are pleased with our results for the quarter, which keep us on track to deliver on our full year revised revenue and earnings commitments. 2014 has been a challenging year in which CONMED has undergone some significant changes. We are working diligently to enhance fundamental strengths of our business to reestablish top line growth while continuing to deliver leveraged earnings growth," commented Curt R. Hartman, Interim Chief Executive Officer. "We thank our shareholders and employees alike who have shared important ideas focused on value creation for all CONMED stakeholders."

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
• Atossa Genetics (ATOS) Tops Q2 EPS by 10c
• Minerva Neurosciences (NERV) Tops Q2 EPS by 5c